自身免疫性肝炎与慢性乙型肝炎患者肝组织MUM-1表达的差异

doi:10.3969/j.issn.1672-5069.2014.06.019

Abstract

Jiang Lilin, Lu Zhonghua, Gu Juan. Expression of multiple myeloma oncogene 1 inplasma cells and plasma cell precursors in patients with autoimmune hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 636-639.

References

[1] Wang PZ. Autoimmune hepatic disease and autoantibodies. Clin Focus,2005,20（4）:230-232.
[2] 霍颖颖,潘毅,管冰心,等. MUM-1/IRF4在滤泡性淋巴瘤中的表达及意义. 中华病理学杂志,2011,40（8）：528-531.
[3] Manns MP,Czaja AJ,Gorham JD,et a1. Diagnosis and management of auto-immune hepatitis. Hepatology,2010,51（6）:2193-2213.
[4] Qiu D,Wang Q,Wang H. Validation of the simplified criteriafor diagnosis of autoimmune hepatitis in Chinese patients.Hepatology,2011,54（2）:340-347.
[5] Daniels JA,Torbenson M,Anders RA,et al.Immunostaining of plasma cells in primary biliary cirrhosis. Am J Clin Pathol,2009,131（2）:243-249.
[6] 丁红兵,陈育霞,杨环文,等. 自身免疫性肝炎与原发性胆汁性肝硬化患者血生化和肝组织病理学分析.实用肝脏病杂志,2014,17（1）：84-85.
[7] 王泰龄,赵新颜.自身免疫性肝炎的病理特点.临床肝胆病杂志,2011,27（6）：577-580.
[8] Mamane Y,Heylbroeck C,Genin P. Interferon regulatory factors:the next generation.Gene,1999,237（1）:1.
[9] Falini B,Fizzotti M,Pucciarini A,et al. A monoclonal antibody（MUM1p）detects expression of the MUM-1/IRF4 proteininasubset of germinal center B cells,plasma cells,and activated T cells. Blood,2000,95:2084-2092.
[10] Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol,2005,6:345-352.
[11] Longhi MS,Hussain MJ,Mitry RR,et al. Functional study of CD4 + CD25 + regulatory T cells in health and autoimmune hepatitis.Immunology,2006,176:4484-4491.
[12] Hori S,Nomura T,Sakaguchi S,et al.Control of regulatory T cell development by the transcription factor Foxp3.Science,2003,299：1057-1061.
[13] Wahl SM,Vazquez N. Chert WJ,el al.Regulatory T cells and transcription factors：Gatekeepers in allergic inflammation.Cur OpinImmunol,2004,16:768-774.
[14] 李明,诸葛洪祥,朱传武,等. 自身免疫性肝炎CD4 + CD25 + high调节性T细胞的研究.中华实验和临床病毒学杂志,2007,21（4）：337-339.
[15] Lafdil F,Miller AM,Ki SH,et al.Th17 cells and their associated cytokines in liver diseases.Cell Mol Immunol,2010,7（4）：250-254.
[16] Zhao L,Qiu de K,Ma X.Th17 cells：the emerging reciprocalpartner of regulatory T cells in the liver. J Dig Dis,2010,11:126-133.
[17] 鲁沛,贾继东.自身免疫性肝炎发病机制的研究进展.肝脏,2011,16（5）：411-414.
[18] Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol, 2007,23（3）:255-262.
[19] 顾珺,沈朝斌,王裕发.干扰素调节因子4对淋巴细胞调控研究进展,国际儿科学杂志,2011,38（4）：410-412.
[20] Biswas PS,Bhagat G,Pernis AB. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis?Immunol Rev,2010,233（1）：79-96.

Expression of multiple myeloma oncogene 1 inplasma cells and plasma cell precursors in patients with autoimmune hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Wang Daowei, Fang Jian, Fan Ling.. Implication of serum IL-21 and chemokine levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2019, 22(6): 844-847.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[10]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.